There were no clinically appropriate changes when compared with 2011 except for new info and new tips with regards to the cure with bisphosphonates and denosumab (see area ‘Bisphosphonates and RANKL Antibody Denosumab’). In sufferers obtaining neoadjuvant therapy, the tumor really